In recent years novel implants in particular have already proven to contribute substantially to enhanced quality of life, higher efficacy of therapeutic approaches, as well as patient safety. With the purpose to optimize the implant-tissue interaction the focus of efforts is on implants with a controlled, site-selective drug release. Therefore, we develop within the REMEDIS consortium implant-associated local drug delivery (LDD) systems for different medical applications. Engineering and natural scientists together with medical experts from all over Germany work in close collaboration to develop such innovative implants which combine the function as medical device and as LDD system. These include vascular stents and stimulation electrodes for the circulatory system and the ears, glaucoma stents for the eyes as well as auditory tube stents for the ears. Through its efforts to combine a LDD system into the functionality of implants, REMEDIS provides cutting-edge research into such medical technology.
Introduction
With the purpose to optimize the implant-cell/tissue interaction a lot of surface modification strategies were investigated and established in the last 10 years. Today, many implants, such as stents, are equipped with drug-containing polymeric coatings in order to obtain local drug delivery (LDD) systems with controlled and sustained rates of drug release [1] [2] [3] . Besides the benefit that the drug is fixed on the implant's surface and relatively protected against mechanical stress, a polymeric coating allows a wide range of control over the release characteristics of the drug. These LDD systems are preferred diffusion-controlled and can be realized by dip-coating, spray-coating techniques. Furthermore, chemically-controlled LDD systems are under consideration, which allow the immobilization of biomolecules, such as growth factors, antibodies and RGD peptides. For chemically controlled, stimulus-responsive LDD systems on the basis of hydrogels the stimulus can be caused by changes of pH and temperature as well as by electric fields [4, 5] . Implants providing controlled, local release of active substances are of interest in different medical applications. Examples of them are described in the following passages.
Vascular stents
Beyond their originally sole mechanical function, current drug-eluting stents (DES) implement the concept of local drug delivery for the re-opening of stenotic arterial vessels, and for prevention of in-stent restenosis as one of the major limitations of conventional bare metal stents (BMS) (Image 1 
Microstents
The use of stents in the eye and the middle ear and the development of the minimally invasive microsurgical techniques for their implantation are opening up new therapeutic options for patients suffering from glaucoma or chronic middle ear inflammation. Due to the location in which they are implanted and to conditions in their immediate environment, both glaucoma stents (Image 3) -as implants used for reducing pressure inside the eye are called -and auditory tube stents, which are used for aerating the middle ear, need to be designed with particular care in terms of function and tissue tolerance. They can be made out of either shape-memory alloys or polymers. Due to their size, micro-structure and biofunctional surfaces, microstent systems pose formidable scientific challenges, challenges that are met by REMEDIS right up to the stage of manufacturing stent prototypes.
Image 3 Schematic of a glaucoma stent implanted from the anterior chamber towards the fat tissue of the eye.
Methods
For the surface modification of vascular stents and stimulation electrodes for the circulatory system and the ears, glaucoma stents as well as auditory tube stents using pol- 
Results
Different diffusion-and chemically controlled LDD systems on the basis of biodegradable polymers, such as polylactides and polyhydroxybutyrates were developed. It was demonstrated that the drug release behavior of diffusion-controlled LDD systems can be designed by the kind of the polymer (hydrophilic/hydrophobic) and the drug (hydrophilic/hydrophobic, lipophilic), the polymer/drug ratio and the surface/volume ratio. In case of chemically controlled LDD systems the drug release can be influenced by the degradation behavior of the used biodegradable coating/covering matrices and the kind of the interaction (non-covalent/covalent, non-hydrolyzable/ hydrolyzable) for chemically linked bioactive substances. Examples of developed implant-associated LDD systems are demonstrated in the following.
Drug-eluting multi-mode stents
Within the REMEDIS consortium novel stents were developed, which address the processes of proliferation and migration of SMCs and re-endothelialization individually and locally selective. This research included the morphological characterization of the locally focussed coatings and the investigation of the in vitro drug release. The in vitro drug release profiles determined by use of HPLC are shown exemplarily in Image 5.
Image 5
Cumulative drug release of a poly(L-lactide) (PLLA)-based drug-eluting multi-mode stent prototype *) in isotonic NaCl solution supplemented with 0.05% (w) Brij 35 and 3 mg/l butylhydroxytoluene at 23°C.
Further investigations were performed regarding the surface activation of biodegradable, polymeric coatings by use of plasma-and wet-chemical processes. With the purpose to prevent the nonspecific protein adsorption protein-repellent spacer molecules were included. Then antibodies as capture molecules for endothelial progenitor cells were immobilized via physical adsorption, carbodiimide crosslinking and site-selective coupling. The antibody surface density and capture capacity were determined by means of ELISA. With the purpose to improve the hemocompatibility and endothelialization of poly(ε-caprolactone) (PCL), intended as material for vascular implants, the antiinflammatory and antithrombogenic model drug acetylsalicylic acid (ASA) and the vascular endothelial growth factor (VEGF) were immobilized by employing N,Ndisuccinimidyl carbonate (DSC) as crosslinker. The release studies showed that the immobilization of ASA and VEGF on the modified PCL surface via DSC is greatly improved compared to adsorption as reference [6] . As advantage of DSC was demonstrated that the immobilization can be realized via non-hydrolyzable and/or hydrolyzable covalent bonding (Image 6).
Image 6 Reaction scheme of VEGF coupling on PCL surface via DSC (i) coupling of DSC, (ii) coupling of VEGF and (iii) VEGF release by hydrolysis, according to [6] .
Drug-eluting electrodes
Within the REMEDIS consortium novel coating strategies were developed which allow the generation of firmly adherent biodegradable coatings on the surface of siliconebased electrode arrays. For it, plasma-and wet-chemical methods were established to activate the chemically relatively inert silicone surface. The generated functional groups were used for binding the biocompatible, polymeric undercoating based on the biodegradable polyesters poly(L-lactide) (PLLA) or poly(4-hydroxybutyrate) (P(4HB)). In this context, an activation step by O 2 plasma was established in order to generate -OH groups on the silicone surface that act as reactive terminal groups for the following modification steps. Since reactive groups like -OH on silicone surfaces are not very persistent and vanish after a short time, 3-aminopropyltriethoxysilane was used to yield stable -NH 2 groups on the surface. Then dexamethasone (DMS)-containing polymeric coatings were applied to the silicone samples by a spray-coating process. The in vitro drug release behavior of such coated silicone samples determined by HPLC is demonstrated in Image 7.
Image 7
Cumulative drug release of silicone samples coated with polymer/DMS (each with n=5) in isotonic NaCl solution at 37°C under quasi-stationary conditions according to [7] .
Glaucoma stents
To prevent the clogging of the microstent structure biodegradable glaucoma stent prototypes consisting of a customized, polymeric blend of P(4HB) and atactic, amorphous poly(3-hydroxybutyrate) (P(3HB)) (50/50 % w/w) were equipped with antiproliferative coatings based on P(4HB) and sirolimus (SIR). As result of the microscopic evaluation can be stated that the surface roughness of the polymeric stents can be reduced by P(4HB)-based coatings (Image 8).
Image 8 Micrographs of uncoated (left) and coated (right) polymeric glaucoma stent prototypes *) .
*) The stent prototypes with the tubing dimensions of ID = 0.3 mm, OD = 0.5 mm and l = 20 mm were manufactured in a dip-coating process. Then 10 mm of the stent outflow area were spray-coated with a mixture of P(4HB) and SIR (P(4HB)/SIR 70/30 % w/w, SIR content approx. 1.4 µg mm -²).
The in vitro SIR release of three coated stents was analyzed in phosphate buffered saline by means of HPLC, according to [8] . The results of in vitro SIR release are shown in Image 9. The analyzed glaucoma stents revealed comparable release kinetics. An initial burst release of over 70 % of the embedded SIR within the first 33 h is followed by a continuous SIR release over a time interval of up to 10 d.
Image 9
Cumulative drug release of P(4HB)/at. P(3HB) (50/50 % w/w) glaucoma stents coated with P(4HB)/SIR (70/30 % w/w) in phosphate buffered saline at 37°C.
Conclusion
Under consideration of the achieved differential and siteselective release of bioactive substances the developed implant-associated, diffusion-or chemically controlled LDD systems have a high potential for the described medical applications. In this context, the developed concepts can be significant for optimized implant-tissue interactions and decreased implant failures.
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